Effect of phenytoin on protein binding of valproic acid. 1979

J Bruni, and J M Gallo, and B J Wilder

In vitro experiments using the equilibrium dialysis technique were performed to determine the binding of valproic acid to plasma components in the absence and presence of therapeutic concentrations of phenytoin. The free fraction of valproic acid was found to be dependent on the total valproic acid concentration. Phenytoin did not influence valproic acid protein binding.

UI MeSH Term Description Entries
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014635 Valproic Acid A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. Dipropyl Acetate,Divalproex,Sodium Valproate,2-Propylpentanoic Acid,Calcium Valproate,Convulsofin,Depakene,Depakine,Depakote,Divalproex Sodium,Ergenyl,Magnesium Valproate,Propylisopropylacetic Acid,Semisodium Valproate,Valproate,Valproate Calcium,Valproate Sodium,Valproic Acid, Sodium Salt (2:1),Vupral,2 Propylpentanoic Acid

Related Publications

J Bruni, and J M Gallo, and B J Wilder
December 1979, British journal of clinical pharmacology,
J Bruni, and J M Gallo, and B J Wilder
December 1978, British journal of clinical pharmacology,
J Bruni, and J M Gallo, and B J Wilder
January 1979, Therapeutic drug monitoring,
J Bruni, and J M Gallo, and B J Wilder
December 1980, Clinical pharmacology and therapeutics,
J Bruni, and J M Gallo, and B J Wilder
May 1993, Biopharmaceutics & drug disposition,
J Bruni, and J M Gallo, and B J Wilder
August 1991, Biochemical pharmacology,
J Bruni, and J M Gallo, and B J Wilder
December 1987, Therapeutic drug monitoring,
J Bruni, and J M Gallo, and B J Wilder
January 1989, European journal of clinical pharmacology,
J Bruni, and J M Gallo, and B J Wilder
January 1979, Therapeutic drug monitoring,
J Bruni, and J M Gallo, and B J Wilder
February 1997, The American journal of the medical sciences,
Copied contents to your clipboard!